Bora Pharmaceuticals Co., LTD. (TPE: 6472)
Taiwan
· Delayed Price · Currency is TWD
818.00
+27.00 (3.41%)
Jan 21, 2025, 1:30 PM CST
Bora Pharmaceuticals Co., LTD. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Revenue | 16,705 | 14,200 | 10,494 | 4,900 | 1,800 | 1,529 | Upgrade
|
Revenue Growth (YoY) | 2.53% | 35.31% | 114.18% | 172.28% | 17.68% | 11.42% | Upgrade
|
Cost of Revenue | 9,175 | 7,209 | 7,582 | 3,228 | 1,096 | 886.18 | Upgrade
|
Gross Profit | 7,530 | 6,991 | 2,913 | 1,672 | 703.88 | 643.03 | Upgrade
|
Selling, General & Admin | 2,977 | 1,444 | 861.52 | 584.52 | 441.16 | 258.54 | Upgrade
|
Research & Development | 565.21 | 298.16 | 129.08 | 41.27 | 36.65 | 39.65 | Upgrade
|
Operating Expenses | 3,542 | 1,742 | 990.6 | 625.79 | 477.81 | 298.19 | Upgrade
|
Operating Income | 3,988 | 5,249 | 1,922 | 1,046 | 226.08 | 344.85 | Upgrade
|
Interest Expense | -397.17 | -171.24 | -108.73 | -53.62 | -21.97 | -14.54 | Upgrade
|
Interest & Investment Income | 92.88 | 62.95 | 11.36 | 0.22 | 0.96 | 2.45 | Upgrade
|
Currency Exchange Gain (Loss) | -162.59 | -67.51 | 47.92 | -14.41 | -11.91 | -7.69 | Upgrade
|
Other Non Operating Income (Expenses) | 86.38 | 39.98 | 17.41 | 48.02 | 14.28 | 1.39 | Upgrade
|
EBT Excluding Unusual Items | 3,607 | 5,113 | 1,890 | 1,026 | 207.43 | 326.46 | Upgrade
|
Gain (Loss) on Sale of Investments | -205.24 | -1,044 | -47.79 | - | 0.11 | 0.03 | Upgrade
|
Gain (Loss) on Sale of Assets | -0.16 | -5 | -2.36 | -2.24 | -0 | -1.13 | Upgrade
|
Other Unusual Items | 1,490 | - | - | - | 387.86 | - | Upgrade
|
Pretax Income | 4,891 | 4,064 | 1,840 | 1,024 | 595.4 | 325.35 | Upgrade
|
Income Tax Expense | 897.11 | 992.23 | 438.48 | 274.23 | 16.97 | 20.32 | Upgrade
|
Earnings From Continuing Operations | 3,994 | 3,072 | 1,402 | 749.74 | 578.43 | 305.03 | Upgrade
|
Minority Interest in Earnings | -94.19 | -41.78 | -9.61 | - | - | - | Upgrade
|
Net Income | 3,900 | 3,030 | 1,392 | 749.74 | 578.43 | 305.03 | Upgrade
|
Net Income to Common | 3,900 | 3,030 | 1,392 | 749.74 | 578.43 | 305.03 | Upgrade
|
Net Income Growth | 35.97% | 117.70% | 85.65% | 29.62% | 89.63% | -31.12% | Upgrade
|
Shares Outstanding (Basic) | 101 | 100 | 98 | 97 | 96 | 89 | Upgrade
|
Shares Outstanding (Diluted) | 106 | 104 | 99 | 97 | 97 | 90 | Upgrade
|
Shares Change (YoY) | 3.82% | 4.93% | 1.40% | 0.86% | 7.55% | 7.29% | Upgrade
|
EPS (Basic) | 38.47 | 30.20 | 14.26 | 7.73 | 6.04 | 3.41 | Upgrade
|
EPS (Diluted) | 37.12 | 29.39 | 14.13 | 7.71 | 6.00 | 3.40 | Upgrade
|
EPS Growth | 31.75% | 107.94% | 83.40% | 28.53% | 76.28% | -35.90% | Upgrade
|
Free Cash Flow | 1,966 | 4,316 | 1,815 | 1,073 | 28.56 | -465.56 | Upgrade
|
Free Cash Flow Per Share | 18.54 | 41.68 | 18.39 | 11.03 | 0.30 | -5.19 | Upgrade
|
Dividend Per Share | 12.000 | 12.000 | 6.159 | 2.449 | 1.123 | 0.864 | Upgrade
|
Dividend Growth | 94.84% | 94.84% | 151.52% | 118.15% | 29.99% | -13.34% | Upgrade
|
Gross Margin | 45.08% | 49.23% | 27.76% | 34.12% | 39.11% | 42.05% | Upgrade
|
Operating Margin | 23.87% | 36.97% | 18.32% | 21.35% | 12.56% | 22.55% | Upgrade
|
Profit Margin | 23.35% | 21.34% | 13.26% | 15.30% | 32.14% | 19.95% | Upgrade
|
Free Cash Flow Margin | 11.77% | 30.39% | 17.30% | 21.90% | 1.59% | -30.44% | Upgrade
|
EBITDA | 4,714 | 5,734 | 2,169 | 1,211 | 354.25 | 452.04 | Upgrade
|
EBITDA Margin | 28.22% | 40.38% | 20.67% | 24.72% | 19.69% | 29.56% | Upgrade
|
D&A For EBITDA | 726.77 | 485.11 | 246.69 | 165.27 | 128.17 | 107.19 | Upgrade
|
EBIT | 3,988 | 5,249 | 1,922 | 1,046 | 226.08 | 344.85 | Upgrade
|
EBIT Margin | 23.87% | 36.97% | 18.32% | 21.35% | 12.56% | 22.55% | Upgrade
|
Effective Tax Rate | 18.34% | 24.41% | 23.83% | 26.78% | 2.85% | 6.25% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.